

BOULE DIAGNOSTICS – INVITATION TO PRESENTATION OF THE INTERIM REPORT Q2 2025

Boule Diagnostics AB will publish the interim report for the period April-June 2025 at 08:00, Friday, July 18, 2025. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger Lembrér will present and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.

The interim report will be accessible at www.boule.com when published.

Enter the Teams live event and download presentation material at: <https://boule.com/investor-relations/>

Contacts

Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0)70-558 51 05

Holger Lembrér, CFO, holger.lembrier@boule.com, phone +46 (0)72-230 77 10

About Us

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 558 million in 2024 and has more than 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. <http://www.boule.com>